SEARCH LISTED COMPANY
ANY AUS OR NZ COMPANY
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
Liberty Place Level 41 161 Castlereagh St Sydney NSW 2000 Locked Bag A14 Sydney South NSW 1235
Tel : 1300 554 474The suspension of trading in the securities of Mesoblast Limited will be lifted immediately following the release by MSB of an announcement regarding a private placement. | 26/04/2023 |
The company releases a notice of proposed issue of securities. | 26/04/2023 |
The company has completed a global private placement primarily to Mesoblast's existing major US, UK, and Australian shareholders raising approximately US$40 million, net of transaction costs, at A$0.85 per share. | 26/04/2023 |
The securities of Mesoblast Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of MSB, pending the release of an announcement regarding a private placement. | 24/04/2023 |
The suspension of trading in the securities of Mesoblast Limited will be lifted immediately following the release by MSB of an announcement regarding a capital raising. | 09/08/2022 |
The company has completed a US$45 million (A$65 million) financing via the issue of 86.7 million fully-paid, ordinary shares in a global private placement led by its largest shareholder, M&G Investments, United Kingdom, and strongly supported by its major Australian and American shareholders. The private placement was made at A$0.75 per share, a 5% discount to the thirty trading-day volume weighted average price (VWAP), without any associated warrants or options. Inclusive of the US$45 million private placement, pro-forma cash-on-hand at June 30, 2022 is approximately US$105.5 million. | 09/08/2022 |
The securities of Mesoblast Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of MSB, pending the release of an announcement regarding a capital raising. | 08/08/2022 |
The securities of Mesoblast Limited (the "Company") will be reinstated to quotation immediately, following the release of an announcement by the Company. | 14/06/2016 |
The company provides an update on its global heart failure program. | 14/06/2016 |
The company advises that the suspension of trading in its securities will remain in place pending an announcement regarding material corporate developments with respect to certain assets of the Company. The Company expects the voluntary suspension to remain in place until the earlier of the commencement of trading on 14 June 2016 and the Company making an announcement with respect to the corporate developments. | 10/06/2016 |
The securities of Mesoblast Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company. | 03/06/2016 |
The securities of Mesoblast Limited (the "Company") will be reinstated to quotation immediately, following the release of an announcement by the Company. Security Code: MSB | 16/11/2015 |
Mesoblast Limited (ASX:MSB; NASDAQ:MESO) today announced it had listed on the Nasdaq Global Market on 13 November under the symbol "˜MESO | 16/11/2015 |
Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that it has filed a US registration statement on Form F-1 with the U.S. Securities and Exchange Commission, offering 5,742,510 American Depositary Shares (ADSs) in the United States, with each ADS representing five fully paid ordinary shares of Mesoblast (Shares). The actual number of ADSs and the issue price, in U.S. dollars, will be determined by Mesoblast in conjunction with the Company's underwriters at the conclusion of the offer process. | 03/11/2015 |
Mesoblast Limited (ASX: MSB, USOTC: MBLTY) announced today that it plans to conduct a registered initial public offering in the United States. Mesoblast has previously submitted to the U.S. Securities and Exchange Commission (the "SEC") a draft registration statement. Mesoblast intends to publicly file its registration statement with the SEC and commence the offering next week. | 30/10/2015 |
The company lodges its quarterly report. | 30/10/2015 |
The securities of Mesoblast Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company. Security Code: MSB | 30/10/2015 |
shares reinstated to quotation | 12/05/2010 |
the securities of Mesoblast Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company | 05/05/2010 |
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 11/09/2025 | Gregory George | 12,899,082 | $1.461 | $18,848,477.00 |
| 10/03/2025 | Gregory George | 74,621 | $1.288 | $96,109.00 |
| 03/03/2025 | Gregory George | 4,551,282 | $1.593 | $7,251,558.00 |
| 28/02/2025 | Eric Rose | -196,092 | $2.497 | $489,542.00 |
| 28/02/2025 | Jane Bell | 79,051 | $2.530 | $199,999.00 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Jane Bell | Non Exec Chairman | 18/08/2022 |
| Joseph Swedish | Non Exec Chairman | 19/06/2018 |
| William Burns | Vice Chairman | 06/03/2014 |
| Silviu Itescu | Managing Director, CEO | 08/06/2004 |
| Dagmar Rosa-Bjorkeson | COO | 24/07/2020 |
| Andrew Chaponnel | CFO | 30/08/2021 |
| Philip Krause | Director | 24/03/2022 |
| Gregory George | Director | 24/02/2025 |
| Eric Rose | Director | 17/04/2013 |
| Lyn Cobley | Director | 29/04/2025 |
| Philip Facchina | Director | 29/03/2021 |
| Paul Hughes | Company Secretary | |
| Niva Sivakumar | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|
Date of first appointment, title may have changed.
